ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Kea, Montes Leave DCPC; Smart Heads Early Detection Branch; Costlow Special Assistant

October 3, 1986

Conversation with The Cancer Letter: Pat White: NIH Funding “Our Only Concern”

September 26, 2014

ASCO Awards Contract For D.C. Office

January 5, 1990

$3.3 Million For Retinoid Contract Awarded

October 14, 1977

NCI To Invite Unaffiliated Oncologists To Enroll Patients On Phase III Trials

May 10, 2002

High Risk Youth Targeted In Concept Ok’d By Advisors

February 8, 1991